(lp0
S'Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation ... GlobeNewswire  - Sep 15, 2016 CAMBRIDGE, Mass., Sept. 15, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from&nbsp;...'
p1
aS'Epizyme President of Research and Chief Scientific Officer, Robert Copeland ... GlobeNewswire  - Mar 9, 2017 CAMBRIDGE, Mass., March 09, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert&nbsp;...Epizyme Inc.  Breaks into New 52-Week High on March 09 Session - Equities.comEpizyme  Reports A Narrower Q4 Loss - Zacks.com'
p2
aS'Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call ... GlobeNewswire  - Feb 27, 2017 CAMBRIDGE, Mass., Feb. 27, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast at 8:30&nbsp;...Analysts Set Epizyme Inc  PT at $20.75 - Chaffey Breeze'
p3
aS'Epizyme Elects Kevin Conroy to its Board of Directors GlobeNewswire  - Feb 7, 2017 CAMBRIDGE, Mass., Feb. 07, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy,&nbsp;...'
p4
aS"Cann Reaffirms Outperform Rating for Epizyme Inc  The Cerbat Gem - 23 hours ago Epizyme Inc logo Cann reaffirmed their outperform rating on shares of Epizyme Inc  in a report published on Wednesday.The Analysts Offer Predictions for Epizyme, Inc.'s Q1 2017 Earnings  - Petro Global News 24"
p5
aS'Epizyme Announces Presentation at JP Morgan 35th Annual Healthcare Conference GlobeNewswire  - Jan 3, 2017 CAMBRIDGE, Mass., Jan. 03, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will&nbsp;...'
p6
aS'Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and ... GlobeNewswire  - Sep 29, 2016 CAMBRIDGE, Mass., Sept. 29, 2016  -- Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the&nbsp;...'
p7
aS'Epizyme Establishes Collaboration with Foundation Medicine to Support ... GlobeNewswire  - Sep 21, 2016 CAMBRIDGE, Mass., Sept. 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement&nbsp;...'
p8
aS"Epizyme Provides Update on Execution of Clinical Program and Reports Third ... GlobeNewswire  - Nov 3, 2016 CAMBRIDGE, Mass., Nov. 03, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today recapped recent progress of the Company's clinical-stage programs and&nbsp;..."
p9
aS'Epizyme President of Research and Chief Scientific Officer Named AAAS Fellow GlobeNewswire  - Nov 21, 2016 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.'
p10
a.